
FIGURE 1A






FIGURE 1B


1 2 3 4

CMT.64 RMA RMA-S

IFN-g - + -


14.3 kd ---


CMT 64 +/- VSV; Superinfection with Vac, or Vacb2




Art Sales Sales


en de la composition La composition de la










	CMT		RI	RMA		RMA-S	
· •				i	, , _		
`,	· 1.	2	ِ 3 .	.4	5	. O	
IFN-g	` ` ,	` 1 -	. ^_`.	+	" ,	+ ;	
	FACILITY		82.	··· • ···		- ^	
-					T. 4. 5. 3.		
			346	2000		336.42	
TAP 1		,		4			
			25 m	بۇ. يونىش	sie si	-	
			-	Co. L	Sey if	N. P.	
		15					
` ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '			- 12	1,1-	- 1	، کینی برانشدند.	
					· · · · · · · · · · · · · · · · · · ·	, ,	
. 70					5: ; ·	~ 73	
	·		12 m	23.50	÷	, ,	
· · · · · · · · · · · · · · · · · · ·	1123	15.		300	A Sec. Mar.	Sant	
(FD 4 70 0)	3	D					
TAP 2	* * * * * * * * * * * * * * * * * * * *	1		154			
	- ; - ;	The same		92.			
		2			also Sites		
	2,1,3,		7			1000	
			3 14	Series?		,,,,	
					~	7. 7	
				-111 3x -w-4 x			
			, ,		`,```	· ·	
	<i>*</i> , :	::\		\$ (; '			
		,,					
ACTIN	~ (• · · ·			•, •	, ;		
	, ,			:	7		
		· Poster	a series	Sec.	Bereit	Co. Co. Co.	
	1	4	46	-	· San Care	Ei.	
	4.17.	- Bearing	a second	in the	Se militaria	The state of the	
• • •	v- ·						




CMT.64 Transfectants +/- VSV










E:1

FIGURE 13

CMT 64 Transfectants +/- VSV



TAP 1 versus TAP 2 CMT 64 Transfectants +/- VSV





FIGURE 15





E:T


CTL Response to Influenza




E:T

Agen.


CTL Response to Influenza




CTL Response to Influenza




CTL Response to HSV-1







A




 \mathbf{B}




A




 ${f B}$






 \mathbf{B}


	VV-NP	VV-NP + VV-hTAP12		
VSV pCTL	1/78,000	1/16,000		




Target RMA + 25µM VSV-Np peptide



T:E Ratio



,





A


Minine Splenocytes


Hum an TAP1

Normal 3X10⁴ 3X10⁵ VV-TAP1,2












FIGURE 32A







FIGURE 32B




TAP1 enhanced the presentation of VSV-NP by B16 cells








TAP1 enhanced the presentation of TRP-2 by B16 cells





Target: Effector ratio

FIGURE 35



Treatment






169 179999 1

	_
1	п
	=
-	

- tomuT	one month		two n	nonths	Ratiob	
	CD4%ª	CD8%	CD4%	CD8%	CD4	CD8
CMTneo	0.54	041				
CMT 1-1	1 02	0.87			19	2 1
CMT 1-4			1 07	1 20	2.0	2.9
CMT.1-10	4.19	294			7 B	72
CMT2-1	0 24	023			04	0.6
CMT2-10	0 12	0 66			02	1.6



in.

